nodes	percent_of_prediction	percent_of_DWPC	metapath
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—IL11RA—ovarian cancer	0.064	0.221	CbGpPWpGaD
Phylloquinone—GGCX—myometrium—ovarian cancer	0.0367	0.118	CbGeAlD
Phylloquinone—BGLAP—embryo—ovarian cancer	0.0362	0.116	CbGeAlD
Phylloquinone—Scleroderma—Paclitaxel—ovarian cancer	0.0361	0.0985	CcSEcCtD
Phylloquinone—Vitamin E—SOD1—ovarian cancer	0.0333	1	CrCbGaD
Phylloquinone—Scleroderma—Docetaxel—ovarian cancer	0.0306	0.0835	CcSEcCtD
Phylloquinone—GGCX—uterine cervix—ovarian cancer	0.0286	0.0919	CbGeAlD
Phylloquinone—GGCX—decidua—ovarian cancer	0.0272	0.0875	CbGeAlD
Phylloquinone—GGCX—endometrium—ovarian cancer	0.0259	0.0831	CbGeAlD
Phylloquinone—GGCX—uterus—ovarian cancer	0.0238	0.0766	CbGeAlD
Phylloquinone—BGLAP—female reproductive system—ovarian cancer	0.0219	0.0705	CbGeAlD
Phylloquinone—GGCX—female reproductive system—ovarian cancer	0.0214	0.0688	CbGeAlD
Phylloquinone—BGLAP—bone marrow—ovarian cancer	0.0207	0.0666	CbGeAlD
Phylloquinone—GGCX—female gonad—ovarian cancer	0.0195	0.0626	CbGeAlD
Phylloquinone—GGCX—vagina—ovarian cancer	0.0194	0.0622	CbGeAlD
Phylloquinone—GGCX—testis—ovarian cancer	0.0173	0.0555	CbGeAlD
Phylloquinone—Phlebitis—Carboplatin—ovarian cancer	0.0156	0.0426	CcSEcCtD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—PARP1—ovarian cancer	0.0129	0.0446	CbGpPWpGaD
Phylloquinone—GGCX—lymph node—ovarian cancer	0.0125	0.0403	CbGeAlD
Phylloquinone—GGCX—Post-translational protein modification—MUC16—ovarian cancer	0.0119	0.0412	CbGpPWpGaD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—SMARCA4—ovarian cancer	0.0116	0.04	CbGpPWpGaD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—SKP2—ovarian cancer	0.011	0.0382	CbGpPWpGaD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—SMARCA4—ovarian cancer	0.00972	0.0336	CbGpPWpGaD
Phylloquinone—Hyperbilirubinaemia—Topotecan—ovarian cancer	0.00933	0.0255	CcSEcCtD
Phylloquinone—Necrosis—Vinorelbine—ovarian cancer	0.00925	0.0253	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—BIRC5—ovarian cancer	0.00905	0.0313	CbGpPWpGaD
Phylloquinone—Injection site pain—Vinorelbine—ovarian cancer	0.00889	0.0243	CcSEcCtD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—CCND2—ovarian cancer	0.00846	0.0292	CbGpPWpGaD
Phylloquinone—Injection site reaction—Melphalan—ovarian cancer	0.00826	0.0226	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—IL6ST—ovarian cancer	0.00769	0.0266	CbGpPWpGaD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP2—ovarian cancer	0.00752	0.026	CbGpPWpGaD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—CCNE1—ovarian cancer	0.00741	0.0256	CbGpPWpGaD
Phylloquinone—Injection site reaction—Vinorelbine—ovarian cancer	0.00722	0.0197	CcSEcCtD
Phylloquinone—BGLAP—FGF signaling pathway—MET—ovarian cancer	0.00666	0.023	CbGpPWpGaD
Phylloquinone—Anaphylactoid reaction—Topotecan—ovarian cancer	0.00637	0.0174	CcSEcCtD
Phylloquinone—Dizziness—Altretamine—ovarian cancer	0.00633	0.0173	CcSEcCtD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CXCL8—ovarian cancer	0.00625	0.0216	CbGpPWpGaD
Phylloquinone—Necrosis—Paclitaxel—ovarian cancer	0.00622	0.017	CcSEcCtD
Phylloquinone—Phlebitis—Vinorelbine—ovarian cancer	0.00612	0.0167	CcSEcCtD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CCND1—ovarian cancer	0.00582	0.0201	CbGpPWpGaD
Phylloquinone—BGLAP—FGF signaling pathway—CDH1—ovarian cancer	0.00577	0.02	CbGpPWpGaD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—MET—ovarian cancer	0.00567	0.0196	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—MUC16—ovarian cancer	0.00566	0.0196	CbGpPWpGaD
Phylloquinone—Pain—Carboplatin—ovarian cancer	0.00566	0.0154	CcSEcCtD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP9—ovarian cancer	0.00565	0.0195	CbGpPWpGaD
Phylloquinone—Hyperbilirubinaemia—Paclitaxel—ovarian cancer	0.00537	0.0147	CcSEcCtD
Phylloquinone—Necrosis—Docetaxel—ovarian cancer	0.00527	0.0144	CcSEcCtD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—CDKN1B—ovarian cancer	0.00504	0.0174	CbGpPWpGaD
Phylloquinone—Injection site reaction—Paclitaxel—ovarian cancer	0.00486	0.0133	CcSEcCtD
Phylloquinone—Hyperbilirubinaemia—Docetaxel—ovarian cancer	0.00455	0.0124	CcSEcCtD
Phylloquinone—Sweating—Topotecan—ovarian cancer	0.00455	0.0124	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—STAT3—ovarian cancer	0.00437	0.0151	CbGpPWpGaD
Phylloquinone—Inflammation—Docetaxel—ovarian cancer	0.00427	0.0117	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—MAPK3—ovarian cancer	0.00418	0.0144	CbGpPWpGaD
Phylloquinone—BGLAP—FGF signaling pathway—MMP9—ovarian cancer	0.00418	0.0144	CbGpPWpGaD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—STAT3—ovarian cancer	0.00415	0.0143	CbGpPWpGaD
Phylloquinone—Injection site reaction—Docetaxel—ovarian cancer	0.00412	0.0112	CcSEcCtD
Phylloquinone—Phlebitis—Paclitaxel—ovarian cancer	0.00412	0.0112	CcSEcCtD
Phylloquinone—Swelling—Paclitaxel—ovarian cancer	0.00402	0.011	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—MAPK1—ovarian cancer	0.00398	0.0137	CbGpPWpGaD
Phylloquinone—Flushing—Melphalan—ovarian cancer	0.00387	0.0106	CcSEcCtD
Phylloquinone—Immune system disorder—Topotecan—ovarian cancer	0.00385	0.0105	CcSEcCtD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—CDKN1B—ovarian cancer	0.00384	0.0133	CbGpPWpGaD
Phylloquinone—Immune system disorder—Melphalan—ovarian cancer	0.00377	0.0103	CcSEcCtD
Phylloquinone—BGLAP—FGF signaling pathway—STAT3—ovarian cancer	0.00371	0.0128	CbGpPWpGaD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—CCND1—ovarian cancer	0.00366	0.0127	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—INHA—ovarian cancer	0.00365	0.0126	CbGpPWpGaD
Phylloquinone—Necrosis—Epirubicin—ovarian cancer	0.00356	0.00971	CcSEcCtD
Phylloquinone—BGLAP—FGF signaling pathway—MAPK3—ovarian cancer	0.00355	0.0123	CbGpPWpGaD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—IL6—ovarian cancer	0.00351	0.0121	CbGpPWpGaD
Phylloquinone—Phlebitis—Docetaxel—ovarian cancer	0.00349	0.00952	CcSEcCtD
Phylloquinone—Injection site pain—Epirubicin—ovarian cancer	0.00342	0.00934	CcSEcCtD
Phylloquinone—Swelling—Docetaxel—ovarian cancer	0.00341	0.0093	CcSEcCtD
Phylloquinone—Flushing—Vinorelbine—ovarian cancer	0.00338	0.00924	CcSEcCtD
Phylloquinone—BGLAP—FGF signaling pathway—MAPK1—ovarian cancer	0.00338	0.0117	CbGpPWpGaD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—CXCL8—ovarian cancer	0.00331	0.0114	CbGpPWpGaD
Phylloquinone—Immune system disorder—Vinorelbine—ovarian cancer	0.00329	0.00899	CcSEcCtD
Phylloquinone—Necrosis—Doxorubicin—ovarian cancer	0.00329	0.00899	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—HRAS—ovarian cancer	0.00319	0.011	CbGpPWpGaD
Phylloquinone—Erythema—Vinorelbine—ovarian cancer	0.00317	0.00867	CcSEcCtD
Phylloquinone—Injection site pain—Doxorubicin—ovarian cancer	0.00316	0.00864	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—IL2—ovarian cancer	0.00316	0.0109	CbGpPWpGaD
Phylloquinone—Hyperbilirubinaemia—Epirubicin—ovarian cancer	0.00307	0.00838	CcSEcCtD
Phylloquinone—Anaphylactic shock—Topotecan—ovarian cancer	0.00303	0.00827	CcSEcCtD
Phylloquinone—Sweating increased—Paclitaxel—ovarian cancer	0.00298	0.00815	CcSEcCtD
Phylloquinone—Anaphylactic shock—Melphalan—ovarian cancer	0.00297	0.0081	CcSEcCtD
Phylloquinone—BGLAP—FGF signaling pathway—PIK3CA—ovarian cancer	0.00293	0.0101	CbGpPWpGaD
Phylloquinone—Hyperhidrosis—Topotecan—ovarian cancer	0.00293	0.00799	CcSEcCtD
Phylloquinone—Pain—Chlorambucil—ovarian cancer	0.00291	0.00794	CcSEcCtD
Phylloquinone—Inflammation—Epirubicin—ovarian cancer	0.00288	0.00786	CcSEcCtD
Phylloquinone—Hyperbilirubinaemia—Doxorubicin—ovarian cancer	0.00284	0.00776	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—AKT1—ovarian cancer	0.00282	0.00974	CbGpPWpGaD
Phylloquinone—Injection site reaction—Epirubicin—ovarian cancer	0.00278	0.00758	CcSEcCtD
Phylloquinone—Hypotension—Melphalan—ovarian cancer	0.00277	0.00756	CcSEcCtD
Phylloquinone—Dyspnoea—Topotecan—ovarian cancer	0.0027	0.00737	CcSEcCtD
Phylloquinone—Inflammation—Doxorubicin—ovarian cancer	0.00266	0.00727	CcSEcCtD
Phylloquinone—Dyspnoea—Melphalan—ovarian cancer	0.00264	0.00722	CcSEcCtD
Phylloquinone—Anaphylactic shock—Vinorelbine—ovarian cancer	0.00259	0.00707	CcSEcCtD
Phylloquinone—Pain—Topotecan—ovarian cancer	0.00259	0.00707	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—TUBB3—ovarian cancer	0.00257	0.00888	CbGpPWpGaD
Phylloquinone—Injection site reaction—Doxorubicin—ovarian cancer	0.00257	0.00701	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—MAPK3—ovarian cancer	0.00254	0.00878	CbGpPWpGaD
Phylloquinone—Pain—Melphalan—ovarian cancer	0.00254	0.00692	CcSEcCtD
Phylloquinone—Hypersensitivity—Chlorambucil—ovarian cancer	0.00251	0.00684	CcSEcCtD
Phylloquinone—Hypotension—Vinorelbine—ovarian cancer	0.00242	0.00661	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—MAPK1—ovarian cancer	0.00242	0.00835	CbGpPWpGaD
Phylloquinone—BGLAP—FGF signaling pathway—AKT1—ovarian cancer	0.00239	0.00827	CbGpPWpGaD
Phylloquinone—Phlebitis—Epirubicin—ovarian cancer	0.00235	0.00642	CcSEcCtD
Phylloquinone—Dyspnoea—Vinorelbine—ovarian cancer	0.00231	0.00631	CcSEcCtD
Phylloquinone—Flushing—Paclitaxel—ovarian cancer	0.00228	0.00621	CcSEcCtD
Phylloquinone—Hypersensitivity—Topotecan—ovarian cancer	0.00223	0.00609	CcSEcCtD
Phylloquinone—Pain—Vinorelbine—ovarian cancer	0.00222	0.00605	CcSEcCtD
Phylloquinone—Immune system disorder—Paclitaxel—ovarian cancer	0.00222	0.00605	CcSEcCtD
Phylloquinone—Hypersensitivity—Melphalan—ovarian cancer	0.00218	0.00596	CcSEcCtD
Phylloquinone—Phlebitis—Doxorubicin—ovarian cancer	0.00218	0.00594	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—ATF3—ovarian cancer	0.00217	0.0075	CbGpPWpGaD
Phylloquinone—Erythema—Paclitaxel—ovarian cancer	0.00214	0.00583	CcSEcCtD
Phylloquinone—Anaphylactoid reaction—Epirubicin—ovarian cancer	0.00209	0.00572	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—TP53—ovarian cancer	0.00203	0.00701	CbGpPWpGaD
Phylloquinone—Dizziness—Topotecan—ovarian cancer	0.002	0.00547	CcSEcCtD
Phylloquinone—Anaphylactoid reaction—Doxorubicin—ovarian cancer	0.00194	0.00529	CcSEcCtD
Phylloquinone—Flushing—Docetaxel—ovarian cancer	0.00193	0.00527	CcSEcCtD
Phylloquinone—Hypersensitivity—Vinorelbine—ovarian cancer	0.00191	0.00521	CcSEcCtD
Phylloquinone—Immune system disorder—Docetaxel—ovarian cancer	0.00188	0.00513	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—IL6—ovarian cancer	0.00186	0.00642	CbGpPWpGaD
Phylloquinone—Erythema—Docetaxel—ovarian cancer	0.00181	0.00494	CcSEcCtD
Phylloquinone—Anaphylactic shock—Paclitaxel—ovarian cancer	0.00174	0.00476	CcSEcCtD
Phylloquinone—Dizziness—Vinorelbine—ovarian cancer	0.00171	0.00468	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—AKT1—ovarian cancer	0.00171	0.00592	CbGpPWpGaD
Phylloquinone—Hyperhidrosis—Paclitaxel—ovarian cancer	0.00168	0.0046	CcSEcCtD
Phylloquinone—Hypotension—Paclitaxel—ovarian cancer	0.00163	0.00445	CcSEcCtD
Phylloquinone—Dyspnoea—Paclitaxel—ovarian cancer	0.00155	0.00424	CcSEcCtD
Phylloquinone—Sweating—Epirubicin—ovarian cancer	0.0015	0.00409	CcSEcCtD
Phylloquinone—Pain—Paclitaxel—ovarian cancer	0.00149	0.00407	CcSEcCtD
Phylloquinone—Anaphylactic shock—Docetaxel—ovarian cancer	0.00148	0.00403	CcSEcCtD
Phylloquinone—Sweating—Doxorubicin—ovarian cancer	0.00139	0.00378	CcSEcCtD
Phylloquinone—Hypotension—Docetaxel—ovarian cancer	0.00138	0.00377	CcSEcCtD
Phylloquinone—Dyspnoea—Docetaxel—ovarian cancer	0.00132	0.0036	CcSEcCtD
Phylloquinone—Flushing—Epirubicin—ovarian cancer	0.0013	0.00355	CcSEcCtD
Phylloquinone—Hypersensitivity—Paclitaxel—ovarian cancer	0.00128	0.00351	CcSEcCtD
Phylloquinone—Immune system disorder—Epirubicin—ovarian cancer	0.00127	0.00346	CcSEcCtD
Phylloquinone—Pain—Docetaxel—ovarian cancer	0.00126	0.00345	CcSEcCtD
Phylloquinone—Erythema—Epirubicin—ovarian cancer	0.00122	0.00333	CcSEcCtD
Phylloquinone—Flushing—Doxorubicin—ovarian cancer	0.0012	0.00329	CcSEcCtD
Phylloquinone—Immune system disorder—Doxorubicin—ovarian cancer	0.00117	0.0032	CcSEcCtD
Phylloquinone—Dizziness—Paclitaxel—ovarian cancer	0.00115	0.00315	CcSEcCtD
Phylloquinone—Erythema—Doxorubicin—ovarian cancer	0.00113	0.00308	CcSEcCtD
Phylloquinone—Hypersensitivity—Docetaxel—ovarian cancer	0.00109	0.00297	CcSEcCtD
Phylloquinone—Anaphylactic shock—Epirubicin—ovarian cancer	0.000996	0.00272	CcSEcCtD
Phylloquinone—Dizziness—Docetaxel—ovarian cancer	0.000977	0.00267	CcSEcCtD
Phylloquinone—Hyperhidrosis—Epirubicin—ovarian cancer	0.000963	0.00263	CcSEcCtD
Phylloquinone—Hypotension—Epirubicin—ovarian cancer	0.000931	0.00254	CcSEcCtD
Phylloquinone—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000922	0.00252	CcSEcCtD
Phylloquinone—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000891	0.00243	CcSEcCtD
Phylloquinone—Dyspnoea—Epirubicin—ovarian cancer	0.000888	0.00242	CcSEcCtD
Phylloquinone—Hypotension—Doxorubicin—ovarian cancer	0.000861	0.00235	CcSEcCtD
Phylloquinone—Pain—Epirubicin—ovarian cancer	0.000852	0.00233	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—MMP2—ovarian cancer	0.000835	0.00289	CbGpPWpGaD
Phylloquinone—Dyspnoea—Doxorubicin—ovarian cancer	0.000822	0.00224	CcSEcCtD
Phylloquinone—Pain—Doxorubicin—ovarian cancer	0.000788	0.00215	CcSEcCtD
Phylloquinone—Hypersensitivity—Epirubicin—ovarian cancer	0.000734	0.002	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—CXCL8—ovarian cancer	0.000694	0.0024	CbGpPWpGaD
Phylloquinone—Hypersensitivity—Doxorubicin—ovarian cancer	0.000679	0.00185	CcSEcCtD
Phylloquinone—Dizziness—Epirubicin—ovarian cancer	0.000659	0.0018	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—CTNNB1—ovarian cancer	0.00064	0.00221	CbGpPWpGaD
Phylloquinone—Dizziness—Doxorubicin—ovarian cancer	0.00061	0.00166	CcSEcCtD
